Abstract: Anti-aging compounds identified using the lead compounds violuric acid and 1-naphthoquinone-2-monoxime are described. The compounds are redox catalysts that appear to improve the function of hematopoietic stem cells. The compounds can be used to decrease the rate of aging in a subject, or to treat or decrease the risk of developing an age-related disease or disorder.

Abstract: Anti-aging compounds identified using the lead compounds violuric acid and 1-naphthoquinone-2-monoxime are described. The compounds are redox catalysts that appear to improve the function of hematopoietic stem cells. The compounds can be used to decrease the rate of aging in a subject, or to treat or decrease the risk of developing an age-related disease or disorder.

Abstract: Naphthalenyl benzamide derivatives according to formula I are described, wherein Ar is an aryl or heteroaryl group, and R1-R4 are independently selected from H, halogen, CF3, hydroxyl, C1-C4 alkyl, and C1-C4 oxyalkyl, or a pharmaceutically acceptable salt thereof. The naphthalenyl benzamide derivatives can be used for the treatment of cancer in a subject.

Abstract: The present disclosure relates generally to drug discovery and development and, more particularly, to in vitro assay systems and methods for selecting lead anti-cancer agents for subsequent testing in human and non-human subjects. The present disclosure allows filtering for candidate anti-cancer agents that are not inactivated by liver enzymes, are able to diffuse through cell layers, are not toxic to bone marrow cells, retain anti-cancer activity in the context of stromal support, and are effective after time-limited exposure mimicking non-hepatic clearance by kidneys and other mechanisms.

Abstract: Protein disulfide isomerase inhibitors according to formula I are described, wherein R1 is an aryl or cycloalkyl group, R2 is selected from the group consisting of CN, SO2CH3, NO2, CO2R3, CONHR3, NMe2, and CF3, R3 is selected from H or lower alkyl, R4 is H, halogen, CN, or COOH, and X and Y are C—H or heteroatoms selected from the group consisting of N, O, and S. The protein disulfide isomerase inhibitors can be used for the treatment of cancer in a subject.

Abstract: The present disclosure relates generally to drug discovery and development and, more particularly, to in vitro assay systems and methods for selecting lead anti-cancer agents for subsequent testing in human and non-human subjects. The present disclosure allows filtering for candidate anti-cancer agents that are not inactivated by liver enzymes, are able to diffuse through cell layers, are not toxic to bone marrow cells, retain anti-cancer activity in the context of stromal support, and are effective after time-limited exposure mimicking non-hepatic clearance by kidneys and other mechanisms.

Abstract: Protein disulfide isomerase inhibitors according to formula I are described, wherein R1 is an aryl or cycloalkyl group, R2 is selected from the group consisting of CN, SO2CH3, NO2, CO2R3, CONHR3, NMe2, and CF3, R3 is selected from H or lower alkyl, R4 is H, halogen, CN, or COOH, and X and Y are C—H or heteroatoms selected from the group consisting of N, O, and S. The protein disulfide isomerase inhibitors can be used for the treatment of cancer in a subject.